Shanghai RAAS Blood Products

Historical price data

Shanghai RAAS's mission is to ensure a stable, safe, and sufficient supply of plasma-derived therapeutics for the Chinese market, serving as a cornerstone of national biosecurity. The company has achieved a leading market position through strategic vertical integration, operating one of the largest networks of plasma collection stations and state-of-the-art fractionation facilities in the country. Its strategy is anchored in scaling plasma collection, expanding its high-value product portfolio (particularly immunoglobulins and factor concentrates), and maintaining technological leadership in viral safety and yield optimization. RAAS is poised for sustained growth driven by rising clinical demand, favorable reimbursement policies, and China's strategic push for plasma product self-sufficiency.

Vertically integrated platform centered on large-scale, GMP-compliant plasma fractionation using cold ethanol methods, coupled with advanced multi-step viral inactivation/removal technologies (solvent/detergent, nanofiltration) to ensure product safety and high yield.

RAAS operates in a domestic oligopoly as one of China's 'Big Four' blood product companies, competing on scale, plasma collection efficiency, and product portfolio depth. It faces limited competition from multinational corporations, which are constrained by import restrictions and national self-sufficiency policies, creating a protected market for established domestic leaders.